You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

SUCRALFATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for sucralfate and what is the scope of patent protection?

Sucralfate is the generic ingredient in two branded drugs marketed by Abbvie, Abon Pharms Llc, Amneal, Hikma, Mylan, Pd Partners, Strides Pharma, Vistapharm Llc, Amneal Pharms, Nostrum Labs Inc, Teva, and Zydus Lifesciences, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for sucralfate. Forty-one suppliers are listed for this compound.

Summary for SUCRALFATE
Drug Prices for SUCRALFATE

See drug prices for SUCRALFATE

Drug Sales Revenue Trends for SUCRALFATE

See drug sales revenues for SUCRALFATE

Recent Clinical Trials for SUCRALFATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cheng-Kung University HospitalN/A
National Cheng-Kung University HospitalPhase 1
Memorial Sloan Kettering Cancer CenterPhase 2

See all SUCRALFATE clinical trials

Pharmacology for SUCRALFATE
Drug ClassAluminum Complex
Medical Subject Heading (MeSH) Categories for SUCRALFATE

US Patents and Regulatory Information for SUCRALFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie CARAFATE sucralfate TABLET;ORAL 018333-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Nostrum Labs Inc SUCRALFATE sucralfate TABLET;ORAL 074415-001 Jun 8, 1998 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Lifesciences SUCRALFATE sucralfate TABLET;ORAL 215705-001 May 3, 2023 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Vistapharm Llc SUCRALFATE sucralfate SUSPENSION;ORAL 211884-001 Mar 15, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abon Pharms Llc SUCRALFATE sucralfate SUSPENSION;ORAL 216726-001 Mar 21, 2024 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.